Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

Sankar, Mari Jeeva; Sankar, Jhuma; Bhat, Vishnu; Srinivasan, Renuka

doi:10.1002/14651858.cd009734

Cited by 34 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, some questions about the long-term outcome compared to conventional laser treatment are still not answered, for example, about development of myopia, vascular changes or size of the visual field, and stage of ROP has also to be considered. [8][9][10] Besides a more detailed evaluation of the questions listed above, it is of great interest if there are other growth factors than VEGF that are involved in pathological neovascularization in the course of ROP, and if their inhibition would have an additional effect on preventing neovascularization.…”

Section: Introductionmentioning

confidence: 99%

Different effects of various anti‐angiogenic treatments in an experimental mouse model of retinopathy of prematurity

Heiduschka

Plagemann

et al. 2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Different effects of various anti‐angiogenic treatments in an experimental mouse model of retinopathy of prematurity

Heiduschka

Plagemann

et al. 2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…VEGF can be secreted by several types of ocular cells [27,28]. The role of VEGF in ocular neovascularization is critical, so VEGF is an attractive target for the development of gene therapies [8][9][10][11][29][30]. Therefore, new effective 9 therapeutic tools that specifically target retinal neovascularization cells and decrease VEGF secretion are urgently needed.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies indicated that anti-VEGF agents can inhibit ocular neovascularization through intravitreal injections [6][7][8][9]. Bevacizumab and ranibizumab have been reported to decrease optic disc edema or to have an anti-inflammatory and anti-neovascular effect on neovascular age-related macular degeneration [6][7][8].…”

mentioning

confidence: 99%

An Endostatin-Lentivirus (ES-LV)-EPC Gene Therapy Agent for Suppression of Neovascularization in Oxygen-Induced Retinopathy Rat Model

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Transplantation of gene transfected endothelial progenitor cells (EPCs) has provided novel methods for tumor neovascularization therapy but not for ocular disease therapy. This study aimed to investigate the efficacy of endostatin transfected EPCs in retinal neovascularization therapy.Results: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed the high expression of endostatin in endostatin-lentivirus-EPCs. The neovascularization leakage area and the number of preretinal neovascular cell nuclei were significantly decreased in the endostatin-lentivirus and endostatin-lentivirus-EPC groups, and the effects of these two treatments on inhibiting retinal neovascularization were almost the same. These two groups also showed the greater retinal distribution of endostatin. Intravitreal injections of endostatin-lentivirus-EPCs inhibited retinal neovascularization, vascular endothelial growth factor (VEGF) and CD31 expression, and increased endostatin expression in vivo. Endostatin-lentivirus-EPCs targeted and prevented pathologic retinal neovascularization.Conclusions: Gene-combined EPCs represent a potential new therapeutic agent for the treatment of neovascular eye diseases.

show abstract

“…Infants born before the end of normal gestation have incomplete and immature retinal vascular development with a peripheral avascular area. ROP occurs as a result of abnormalities in the development of new blood vessels in the avascular area of the retina due to exposure to high oxygen, as the high oxygen is used to assist with lung development and function (136). Thus completion of the retinal vascular development could be delayed even after birth (30,108,145).…”

Section: Retinopathy Of Prematuritymentioning

confidence: 99%

Vitamin D and regulation of vascular cell function

Jamali

Sorenson

Sheibani

2018

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Vitamin D deficiency is linked to pathogenesis of many diseases including cardiovascular, cancer, and various eye diseases. In recent years, important roles for vitamin D in regulation of immune function, inflammation, angiogenesis, and aging have been demonstrated. Thus, vitamin D and its analogs have been evaluated for the treatment of various types of cancer and chronic diseases. We have previously shown that the active form of vitamin D [1,25(OH)D] is a potent inhibitor of angiogenesis. This activity is consistent with the important role proposed for vitamin D and its analogs in the mitigation of tumor growth through inhibition of angiogenesis. Here, we review the important nutritional value of vitamin D and the abnormalities linked to its deficiency. We will explore its potential role as a regulator of angiogenesis and vascular cell function and the role vitamin D receptor (VDR) expression plays in these activities during vascular development and neovascularization. Our studies have established an important role for 1,25(OH)D and VDR in the regulation of perivascular supporting cell function. In addition, the interaction of 1,25(OH)D and VDR is essential for these activities and inhibition of neovascularization. Delineating the signaling pathways involved and identification of genes that are the target of 1,25(OH)D regulation in vascular cells will allow us to identify novel pathways that are targets for regulation of vascular function and angiogenesis.

show abstract

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

Cited by 34 publications

References 17 publications

Different effects of various anti‐angiogenic treatments in an experimental mouse model of retinopathy of prematurity

Different effects of various anti‐angiogenic treatments in an experimental mouse model of retinopathy of prematurity

An Endostatin-Lentivirus (ES-LV)-EPC Gene Therapy Agent for Suppression of Neovascularization in Oxygen-Induced Retinopathy Rat Model

Vitamin D and regulation of vascular cell function

Contact Info

Product

Resources

About